Dyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month Low - Here's Why

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares reached a new 52-week low on Tuesday . The stock traded as low as $9.96 and last traded at $10.46, with a volume of 2930532 shares traded. The stock had previously closed at $11.45.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of recent research reports. Scotiabank started coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective for the company. JPMorgan Chase & Co. dropped their price target on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Royal Bank of Canada restated an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, HC Wainwright restated a "buy" rating and set a $46.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $47.46.

Dyne Therapeutics Price Performance

The firm has a market capitalization of $936.30 million, a P/E ratio of -2.33 and a beta of 1.11. The stock's fifty day simple moving average is $12.92 and its 200 day simple moving average is $22.87.

Remove Ads

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares of the company's stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders sold 6,237 shares of company stock worth $77,760. Company insiders own 20.77% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently modified their holdings of DYN. Janus Henderson Group PLC raised its position in shares of Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock worth $173,808,000 after purchasing an additional 566,146 shares during the last quarter. RTW Investments LP raised its holdings in shares of Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock valued at $244,926,000 after acquiring an additional 431,503 shares during the last quarter. RA Capital Management L.P. lifted its position in shares of Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock valued at $229,211,000 after acquiring an additional 331,940 shares in the last quarter. State Street Corp lifted its position in shares of Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company's stock valued at $130,816,000 after acquiring an additional 440,890 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Dyne Therapeutics by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock worth $44,476,000 after acquiring an additional 27,916 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.